Sarah C Snow1, Gregg C Fonarow2, Joseph A Ladapo1, Donna L Washington3, Katherine J Hoggatt4, Boback Ziaeian5. 1. Division of General Internal Medicine, David Geffen School of Medicine at University of California, Los Angeles. 2. Division of Cardiology, David Geffen School of Medicine at University of California, Los Angeles; Ahmanson-UCLA Cardiomyopathy Center, University of California,Los Angeles Medical Center. 3. Division of General Internal Medicine, David Geffen School of Medicine at University of California, Los Angeles; Division of Health Services Research & Development, Veterans Affairs Greater Los Angeles Healthcare System, Calif. 4. Division of Health Services Research & Development, Veterans Affairs Greater Los Angeles Healthcare System, Calif; Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles. 5. Division of Cardiology, David Geffen School of Medicine at University of California, Los Angeles; Division of Health Services Research & Development, Veterans Affairs Greater Los Angeles Healthcare System, Calif; Divisionof Cardiology, Veterans Affairs Greater Los Angeles Healthcare System, Calif. Electronic address: bziaeian@mednet.ucla.edu.
Abstract
BACKGROUND: Several cardiotoxic substances impact heart failure incidence. The burden of comorbid tobacco or substance use disorders among heart failure patients is under-characterized. We describe the burden of tobacco and substance use disorders among hospitalized heart failure patients in the United States. METHODS: We calculated the proportion of primary heart failure hospitalizations in the 2014 National Inpatient Sample with tobacco or substance use disorders accounting for demographic factors. RESULTS: Of 989,080 heart failure hospitalizations, 15.5% (n = 152,965) had documented tobacco (n = 119,285, 12.1%) or substance (n = 61,510, 6.2%) use disorder. Female sex was associated with lower rates of tobacco (odds ratio [OR] 0.72; 95% confidence interval [CI], 0.70-0.74) and substance (OR 0.37; 95% CI, 0.36-0.39) use disorder. Tobacco and substance use disorder rates were highest for hospitalizations <55years of age. Native American race was associated with increased risk of alcohol use disorder (OR 1.67; 95% CI, 1.27-2.20) and black race with alcohol (OR 1.09; 95% CI, 1.02-1.16) or drug (OR 1.63; 95% CI, 1.53-1.74) use disorder. Medicaid insurance or income in the lowest quartile were associated with increased risk of tobacco and substance use disorders. CONCLUSIONS: Tobacco and substance use disorders affect vulnerable heart failure populations, including those of male sex, younger age, lower socioeconomic status, and racial/ethnic minorities. Enhanced screening for tobacco and substance use disorders in hospitalized heart failure patients may reveal opportunities for treatment and secondary prevention. Published by Elsevier Inc.
BACKGROUND: Several cardiotoxic substances impact heart failure incidence. The burden of comorbid tobacco or substance use disorders among heart failure patients is under-characterized. We describe the burden of tobacco and substance use disorders among hospitalized heart failure patients in the United States. METHODS: We calculated the proportion of primary heart failure hospitalizations in the 2014 National Inpatient Sample with tobacco or substance use disorders accounting for demographic factors. RESULTS: Of 989,080 heart failure hospitalizations, 15.5% (n = 152,965) had documented tobacco (n = 119,285, 12.1%) or substance (n = 61,510, 6.2%) use disorder. Female sex was associated with lower rates of tobacco (odds ratio [OR] 0.72; 95% confidence interval [CI], 0.70-0.74) and substance (OR 0.37; 95% CI, 0.36-0.39) use disorder. Tobacco and substance use disorder rates were highest for hospitalizations <55years of age. Native American race was associated with increased risk of alcohol use disorder (OR 1.67; 95% CI, 1.27-2.20) and black race with alcohol (OR 1.09; 95% CI, 1.02-1.16) or drug (OR 1.63; 95% CI, 1.53-1.74) use disorder. Medicaid insurance or income in the lowest quartile were associated with increased risk of tobacco and substance use disorders. CONCLUSIONS: Tobacco and substance use disorders affect vulnerable heart failure populations, including those of male sex, younger age, lower socioeconomic status, and racial/ethnic minorities. Enhanced screening for tobacco and substance use disorders in hospitalized heart failure patients may reveal opportunities for treatment and secondary prevention. Published by Elsevier Inc.
Entities:
Keywords:
Alcohol; Drug use; Health care disparities; Heart failure; Hospitalization; Substance use; Tobacco
Authors: Boback Ziaeian; Gerald F Kominski; Michael K Ong; Vickie M Mays; Robert H Brook; Gregg C Fonarow Journal: Circ Cardiovasc Qual Outcomes Date: 2017-07
Authors: Gregg C Fonarow; William T Abraham; Nancy M Albert; Wendy Gattis Stough; Mihai Gheorghiade; Barry H Greenberg; Christopher M O'Connor; Eduardo Nunez; Clyde W Yancy; James B Young Journal: Eur Heart J Date: 2008-05-15 Impact factor: 29.983
Authors: Douglas D Schocken; Emelia J Benjamin; Gregg C Fonarow; Harlan M Krumholz; Daniel Levy; George A Mensah; Jagat Narula; Eileen Stuart Shor; James B Young; Yuling Hong Journal: Circulation Date: 2008-04-07 Impact factor: 29.690
Authors: Satomi Odani; Brian S Armour; Corinne M Graffunder; Bridgette E Garrett; Israel T Agaku Journal: MMWR Morb Mortal Wkly Rep Date: 2017-12-22 Impact factor: 17.586
Authors: Sanyog G Shitole; Jason M Lazar; David B Hanna; Ryung S Kim; Kathryn Anastos; Mario J Garcia; Phyllis C Tien; João A C Lima; Robert C Kaplan; Jorge R Kizer Journal: AIDS Date: 2021-08-01 Impact factor: 4.632